The FDA approved an IDE allowing Mercy BioAnalytics to evaluate its Evident blood-based ovarian cancer screening test in the prospective pivotal SOARA study of average-risk women.
|Videos|October 2, 2022
Medications for early pregnancy loss with Amy Levi, CNM, WHNP-BC, FACNM, FAAN
Author(s)Lindsey Carr, Editor
Amy Levi, CNM, WHNP-BC, FACNM, FAAN, Albers Endowed Professor of Midwifery at the University of New Mexico College of Nursing, sits down to discuss her presentation at the NPWH 25th Annual Premier Women's Healthcare Conference on medications for early pregnancy loss.
Advertisement
Advertisement
Related to this article
Sameena Rahman, MD, discusses how digital symptom trackers can shorten PMOS diagnostic delays and support earlier cardiometabolic care.
A new, expert-led video series explores the PCOS-to-PMOS rename and what it means for diagnosis, care, and outcomes.
Seventy-one percent of women miss their first perimenopausal symptom because anxiety, brain fog, and mood changes precede hot flashes—and most attribute them to stress, per the Bonafide 2026 State of Menopause Survey.
A real-world study presented at Psych Congress found that zuranolone's PPD symptom improvements were sustained through day 90.
Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.
Maternal RSV immunization creates an important opportunity for obstetric and pediatric clinicians to coordinate newborn prevention strategies, according to Kevin Ault, MD.
A new Gallup survey found 51% of women in the United States reported negative healthcare experiences.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Zuranolone shows sustained PPD symptom improvement through day 90
2
Emotional and cognitive symptoms are redefining perimenopause recognition
3
Q&A: Sameena Rahman, MD, on digital symptom tracking in PMOS
4
Survey: 51% of US-women report negative healthcare experiences
5